For the seventh consecutive year, the Top Employer Institute has recognized Boehringer Ingelheim as a Top Employer in the ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 ...

Williams, who has performed the National Anthem at baseball stadiums as part of Boehringer Ingelheim’s Breathless campaign, ...

An Illinois jury ruled in favor of Boehringer Ingelheim in Zantac litigation brought by two prostate cancer patients, the ...

Boehringer Ingelheim, the Germany-based research-driven biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with Kenya's Mission for Essential Drugs and Supplies (MEDS) to expand ...

In a significant boost to the nation's poultry industry, Boehringer Ingelheim has announced the launch of its innovative ...

Boehringer Ingelheim and partners have commenced the Phase I/II LENTICLAIR 1 trial of gene therapy BI 3720931 targeting ...

With VAXXITEK® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK® range with a new vaccine that protects ...